Whalesbook
Aisa Kya Hua Zydus Ke Saath? Konsa Wada Tha, Konsa Dhoka?
Dekho, Zydus Lifesciences ne Q3 FY26 ke results toh nikaal diye hain, aur kahani thodi mix hai. Ek taraf, company ki jo consolidated revenue hai na, woh 30.28% zyaada ho gayi saal dar saal, matlab ₹68,645 Million tak pahunch gayi. Iska poora credit jaata hai unke recent acquisitions ko, jaise Amplitude Surgical SA (July 2025 mein) aur Comfort Click Limited (August 2025 mein). Ye nayi companies kaafi achha contribution de rahi hain. Quarter-on-quarter (QoQ) basis par bhi revenue 12.10% badhi hai.
Par ab aate hain asal kaam par – company ke standalone operations pe. Yahan cheezein bilkul ulti hain. Standalone revenue 8.45% kam hokar ₹22,836 Million par aa gayi, jo pichle quarter se 20.45% kam hai. Aur profit ka toh poochho hi mat, seedha 37% gir gaya saal dar saal, ab yeh ₹2,965 Million par hai. Quarter-on-quarter toh 74.36% ka bada drop hai! Standalone EPS bhi gir kar ₹2.95 raha.
Consolidated level par profit before tax toh 14.29% badha hai, ₹13,534 Million tak. Lekin consolidated net profit mein thodi kami aayi hai, yeh 0.35% gir kar ₹10,229 Million raha, jo ki sequential basis par 17.41% kam hai. Consolidated EPS from continuing operations ₹10.36 raha, jo saal dar saal 1.77% upar hai, par quarter dar quarter 17.15% neeche.
Nain Mahino (Nine Months) ka consolidated revenue dekho toh 17.05% badh kar ₹195,614 Million ho gaya hai, aur consolidated net profit 10.31% badh kar ₹37,825 Million raha hai, jiska EPS ₹37.44 hai.
Numbers Ke Peeche Ka Sach Kya Hai?
Is result mein kuch exceptional items bhi the jinhone numbers ko thoda affect kiya hai. Standalone results mein New Labour Codes ki wajah se ₹601 Million ka one-time impact pada. Consolidated level par ₹849 Million ke exceptional items the, jismein New Labour Codes, Brazil business ke goodwill ka impairment, aur Comfort Click Limited ke acquisition expenses shaamil hain.
Aur ek chiz jo investors ko tension de sakti hai, woh hai Consumer Products segment. Iss segment ne iss quarter mein ₹355 Million ka net loss report kiya hai, jo ki kaafi chinta ka vishay hai. Pharmaceutical segment abhi bhi consolidated entity ke liye revenue aur profit ka sabse bada source hai.
Management Kya Keh Raha Hai? (Ya Nahi Keh Raha Hai)
Sabse badi baat, company ne future outlook ya koi forward-looking guidance bilkul nahi diya hai. Matlab, management ne yeh nahi bataya ki aage kya hone wala hai, growth drivers kya honge, ya unki kya plan hai. Yeh cheez investors ke liye thoda uncertainty wala ho sakta hai.
Aage Kya Dekhna Hai?
Ab investors ki nazar is baat par rahegi ki Amplitude Surgical SA aur Comfort Click Limited ka integration kaisa hota hai aur yeh consolidated profitability par kaise asar dalte hain. Standalone business aur Consumer Products segment ke liye company ki kya strategy hai, yeh bhi jaanana zaroori hoga. Management se next update ka intezaar rahega.